Home page Home page

Rotarix
rotavirus vaccine, live

Package leaflet: Information for the user


Rotarix powder and solvent for oral suspension

rotavirus vaccine, live


Read all of this leaflet carefully before your child receives this vaccine because it contains important information for you.


What is in this leaflet

  1. What Rotarix is and what it is used for

  2. What you need to know before your child receives Rotarix

  3. How Rotarix is given

  4. Possible side effects

  5. How to store Rotarix

  6. Contents of the pack and other information


  1. What Rotarix is and what it is used for


    Rotarix is a viral vaccine, containing live, attenuated human rotavirus, that helps to protect your child, from the age of 6 weeks, against gastro-enteritis (diarrhoea and vomiting) caused by rotavirus infection.


    How Rotarix works


    Rotavirus infection is the most common cause of severe diarrhoea in infants and young children. Rotavirus is easily spread from hand-to-mouth due to contact with stools from an infected person. Most children with rotavirus diarrhoea recover on their own. However, some children become very ill with severe vomiting, diarrhoea and life-threatening loss of fluids that requires hospitalisation.


    When a person is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus. These antibodies protect against disease caused by these types of rotavirus.


    As with all vaccines, Rotarix may not completely protect all people who are vaccinated against the rotavirus infections it is intended to prevent.


  2. What you need to know before your child receives Rotarix Rotarix should not be given

    • if your child has previously had any allergic reaction to rotavirus vaccines or any of the other ingredients of this vaccine (listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.

    • if your child has previously had intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment).

    • if your child was born with a malformation of the gut that could lead to intussusception.

    • if your child has a rare inherited illness which affects their immune system called Severe Combined Immunodeficiency (SCID).

    • if your child has a severe infection with a high temperature. It might be necessary to postpone the vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to your doctor first.

    • if your child has diarrhoea or is vomiting. It might be necessary to postpone the vaccination until recovery.


      Warnings and precautions

      Talk to your doctor/health care professional before your child receives Rotarix if:

    • he/she has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system.

    • he/she has any disorder of the gastrointestinal system.

    • he/she has not been gaining weight and growing as expected.

    • he/she has any disease or is taking any medicine which reduces his/her resistance to infection or if his/her mother has taken during pregnancy any medicine that may weaken the immune system.


    After your child has received Rotarix, contact a doctor/health care professional right away if your child experiences severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever (see also section 4 “Possible side effects”).


    As always, please take care to wash your hands thoroughly after changing soiled nappies.


    Other medicines and Rotarix

    Tell your doctor if your child is taking, has recently taken or might take any other medicines or has recently received any other vaccine.


    Rotarix may be given at the same time your child receives other normally recommended vaccines, such as diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b, oral or inactivated polio, hepatitis B vaccines as well as pneumococcal and meningococcal serogroup C conjugate vaccines.


    Rotarix with food and drink

    There are no restrictions on your child’s consumption of food or liquids, either before or after vaccination.


    Breast-feeding

    Based on evidence generated in clinical trials, breast-feeding does not reduce the protection against rotavirus gastro-enteritis afforded by Rotarix. Therefore, breast-feeding may be continued during the vaccination schedule.


    Rotarix contains sorbitol, sucrose, glucose, phenylalanine and sodium

    This vaccine contains 13.5 mg sorbitol in each dose.


    If you have been told by your doctor that the child being vaccinated has an intolerance to some sugars, contact your doctor before your child receives this vaccine.


    This vaccine contains 0.15 microgram phenylalanine in each dose. Phenylalanine may be harmful if your child has phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

    This vaccine contains less than 1 mmol sodium (23 mg) in each dose, that is to say essentially ‘sodium-free’.


  3. How Rotarix is given


    The doctor or nurse will administer the recommended dose of Rotarix to your child. The vaccine (1 ml liquid) will be given orally. Under no circumstance should this vaccine be administered by injection.


    Your child will receive two doses of the vaccine. Each dose will be given on a separate occasion with an interval of at least 4 weeks between the two doses. The first dose may be given from the age of 6

    weeks. The two doses of the vaccine must have been given by the age of 24 weeks, although they should preferably have been given before 16 weeks of age.


    Rotarix may be given according to the same vaccination course to infants who were born prematurely, provided that the pregnancy had lasted at least 27 weeks.


    In case your child spits out or regurgitates most of the vaccine dose, a single replacement dose may be given at the same vaccination visit.


    When Rotarix is given to your child for the first dose, it is recommended that your child also receives Rotarix (and not another rotavirus vaccine) for the second dose.


    It is important that you follow the instructions of your doctor or nurse regarding return visits. If you forget to go back to your doctor at the scheduled time, ask your doctor for advice.


  4. Possible side effects


    Like all medicines, this vaccine can cause side effects, although not everybody gets them. The following side effects may happen with this vaccine:

    • Common (These may occur with up to 1 in 10 doses of the vaccine):

      • diarrhoea

      • irritability


    • Uncommon (These may occur with up to 1 in 100 doses of the vaccine):

      • abdominal pain (see also below for signs of very rare side effects of intussusception)

      • flatulence

      • inflammation of the skin


        Side effects that have been reported during marketed use of Rotarix include:

      • Very rare: hives (urticaria)

      • Very rare: intussusception (part of the intestine gets blocked or twisted). The signs may include severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever. Contact a doctor/health care professional right away if your child experiences one of these symptoms.

      • blood in stools

      • in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.

      • children with a rare inherited illness called Severe Combined Immunodeficiency (SCID) may have an inflamed stomach or gut (gastroenteritis) and pass the vaccine virus in their stools. The signs of gastroenteritis may include feeling sick, being sick, stomach cramps or diarrhoea.


    Reporting of side effects

    If your child gets any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


  5. How to store Rotarix


    Keep this vaccine out of the sight and reach of children.

    Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.


    Store in a refrigerator (2°C – 8°C). Do not freeze.

    Store in the original package in order to protect from light.


    After reconstitution, the vaccine contained in the oral applicator should be administered promptly. If the reconstituted vaccine is not used within 24 hours, it should be discarded.


    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines your child no longer uses. These measures will help to protect the environment.


  6. Contents of the pack and other information What Rotarix contains

    - The active substances are:


    Human rotavirus RIX4414 strain (live, attenuated)* not less than 106.0 CCID50


    *Produced on Vero cells


    - The other ingredients in Rotarix are:

    Powder: dextran, sucrose, sorbitol (E420), amino acids (including phenylalanine), Dulbecco’s Modified Eagle Medium (DMEM) (containing phenylalanine, sodium, glucose and other substances), (see also section 2, “Rotarix contains sorbitol, sucrose, glucose, phenylalanine and sodium”)

    Solvent: calcium carbonate, xanthan gum, sterile water


    What Rotarix looks like and contents of the pack


    Powder and solvent for oral suspension


    Rotarix is supplied as a whitish powder in a single dose glass container and a separate oral applicator of solvent which contains a slow settling white deposit and a colourless supernatant. There is also a transfer adapter which allows easy transfer of the solvent into the glass container containing the powder for mixing the different components of the vaccine.


    Both components must be mixed together before your child receives the vaccine. The mixed vaccine will appear more turbid than the solvent alone.


    Rotarix is available in a pack of 1, 5, 10 or 25. Not all pack sizes may be marketed.

    Marketing Authorisation Holder and Manufacturer


    GlaxoSmithKline Biologicals SA Rue de l’Institut 89

    B-1330 Rixensart Belgium


    For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

    België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals SA/NV Tél/Tel: + 32 10 85 52 00

    Lietuva

    GlaxoSmithKline Biologicals SA Tel. +370 80000334


    България

    GlaxoSmithKline Biologicals SA

    Тел. +359 80018205

    Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals SA/NV Tél/Tel: + 32 10 85 52 00


    Česká republika GlaxoSmithKline s.r.o. Tel: + 420 2 22 00 11 11

    cz.info@gsk.com

    Magyarország GlaxoSmithKline Biologicals SA Tel.: +36 80088309


    Danmark

    GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00

    dk-info@gsk.com

    Malta

    GlaxoSmithKline Biologicals SA Tel: +356 80065004


    Deutschland

    GlaxoSmithKline GmbH & Co. KG Tel: + 49 (0)89 360448701

    produkt.info@gsk.com

    Nederland GlaxoSmithKline BV Tel: + 31 (0)33 2081100


    Eesti

    GlaxoSmithKline Biologicals SA Tel: +372 8002640

    Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00


    Ελλάδα

    GlaxoSmithKline Μονοπρόσωπη A.E.B.E.

    Tηλ: + 30 210 68 82 100

    Österreich

    GlaxoSmithKline Pharma GmbH. Tel: + 43 (0)1 97075 0

    at.info@gsk.com


    España GlaxoSmithKline, S.A. Tel: + 34 900 202 700

    es-ci@gsk.com

    Polska

    GSK Services Sp. z o.o. Tel.: + 48 (22) 576 9000


    France

    Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44

    diam@gsk.com


    Hrvatska

    GlaxoSmithKline Biologicals SA Tel.: +385 800787089

    Portugal

    Smith Kline & French Portuguesa - Produtos Farmacêuticos, Lda.

    Tel: + 351 21 412 95 00

    FI.PT@gsk.com


    România

    GlaxoSmithKline Biologicals SA Tel: +40 800672524


    Ireland

    GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 495 5000

    Slovenija

    GlaxoSmithKline Biologicals SA Tel: +386 80688869


    Ísland

    Vistor hf.

    Sími : +354 535 7000

    Slovenská republika GlaxoSmithKline Biologicals SA Tel: +421 800500589

    Italia

    GlaxoSmithKline S.p.A. Tel:+ 39 (0)45 7741 111

    Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30


    Κύπρος

    GlaxoSmithKline Biologicals SA

    Τηλ: +357 80070017

    Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00

    info.produkt@gsk.com


    Latvija

    GlaxoSmithKline Biologicals SA Tel: +371 80205045

    United Kingdom (Northern Ireland) GlaxoSmithKline Biologicals SA

    Tel: + 44 (0)800 221 441

    customercontactuk@gsk.com


    This leaflet was last revised in.

    .eu.

    -------------------------------------------------------------------------------------------------------------------------

    The following information is intended for healthcare professionals only:


    Before reconstitution:

    A white deposit and clear supernatant is observed upon storage of the oral applicator containing the solvent.

    The solvent should be inspected visually for any foreign particulate matter and/or abnormal physical

    appearance prior to reconstitution.


    After reconstitution:

    The reconstituted vaccine is slightly more turbid than the solvent and is milky white in appearance.


    The reconstituted vaccine should also be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration. In the event of either being observed, discard the vaccine.

    Any unused vaccine or waste material should be disposed of in accordance with local requirements.


    Instructions for reconstitution and administration of the vaccine:


    Transfer adapter


    Glass container


    Oral

    applicator


    Oral applicator Tip-Cap


    1. Remove the plastic cover from the glass container containing the powder


    2. Connect the transfer adapter onto the glass container by pushing it downwards until the transfer adapter is properly and securely placed


    3. Shake the oral applicator containing the solvent vigorously. The shaken suspension will appear as a turbid liquid with a slow settling white deposit



    4. Remove the protective tip cap from the oral applicator


    5. Connect the oral applicator into the transfer adapter by pushing it firmly on this device


    6. Transfer the entire content of the oral applicator into the glass container containing the powder

    7. With the oral applicator still attached, shake the glass container and examine it for complete suspension of the powder. The reconstituted vaccine will appear more turbid than the solvent alone. This appearance is normal


      image

    8. Withdraw the entire mixture back into the oral applicator

    9. Remove the oral applicator from the transfer adapter

    10. This vaccine is for oral administration only. The child should be seated in a reclining position. Administer the entire content of the oral applicator orally (by administering the entire content of the oral applicator on the inside of the cheek)

11. Do not inject.


If the reconstituted vaccine is to be stored temporarily before administration, replace the protective tip cap on the oral applicator. The oral applicator containing the reconstituted vaccine should be shaken gently again before oral administration. Do not inject.